Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera vs Epoetin Alfa Pharmacoeconomic Study in CKD Anemia
NCT00422513Phase 3Terminated
- Sponsor
- Roche
- Start
- Mar 2007
- Primary completion
- Dec 2007
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methoxy polyethylene glycol-epoetin beta in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Roche. Primary endpoints: Time Spent on Anemia Treatment Over Evaluation Period and Change in Hemoglobin Concentration From Baseline to the Average Over the Evaluation Period. Started Mar 2007; status: terminated.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00422513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422513.